Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• "Moderate Buy" consensus from five analysts (four buys, one sell) with an average 12‑month price target of $25, while Guggenheim recently raised its target to $36 and kept a buy rating.
• Institutional investors own about 38.81% of Nanobiotix, with recent new or increased stakes from Millennium Management, Marshall Wace, Optiver and Royal Bank of Canada (RBC boosted its holding 2,000% to 2,625 shares).
• Nanobiotix is a clinical‑stage biotech developing the hafnium‑oxide radioenhancer NBTXR3 (CE marked in Europe for soft tissue sarcoma); it reported quarterly EPS of ($0.23) on $3.42M revenue and the stock trades near $33.71 (52‑week range $3.13–$41.89).

Shares of Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the five analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $25.00.

NBTX has been the topic of several research reports. TD Cowen restated a "buy" rating on shares of Nanobiotix in a report on Thursday, March 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Nanobiotix in a report on Tuesday. Finally, Guggenheim boosted their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a "buy" rating in a report on Thursday, April 2nd.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Millennium Management LLC bought a new position in shares of Nanobiotix during the 4th quarter worth about $390,000. Royal Bank of Canada boosted its position in shares of Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company's stock valued at $61,000 after acquiring an additional 2,500 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Nanobiotix during the 4th quarter valued at about $220,000. Finally, Optiver Holding B.V. acquired a new stake in shares of Nanobiotix during the 3rd quarter valued at about $101,000. Institutional investors own 38.81% of the company's stock.

Nanobiotix Stock Performance

NASDAQ:NBTX opened at $33.71 on Friday. The firm's 50-day moving average is $30.95 and its 200-day moving average is $25.01. Nanobiotix has a 52-week low of $3.13 and a 52-week high of $41.89.

Nanobiotix (NASDAQ:NBTX - Get Free Report) last posted its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The firm had revenue of $3.42 million for the quarter. Sell-side analysts forecast that Nanobiotix will post 0.53 earnings per share for the current year.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company's lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.